BRPI0416812A - métodos e reagentes para o tratamento de desordens inflamatórias - Google Patents

métodos e reagentes para o tratamento de desordens inflamatórias

Info

Publication number
BRPI0416812A
BRPI0416812A BRPI0416812-7A BRPI0416812A BRPI0416812A BR PI0416812 A BRPI0416812 A BR PI0416812A BR PI0416812 A BRPI0416812 A BR PI0416812A BR PI0416812 A BRPI0416812 A BR PI0416812A
Authority
BR
Brazil
Prior art keywords
treatment
reagents
methods
inflammatory disorders
compound
Prior art date
Application number
BRPI0416812-7A
Other languages
English (en)
Inventor
Edward Roydon Jost-Price
Palaniyandi Manivasakam
Brendan Smith
Michael S Slavonic
Benjamin A Auspitz
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of BRPI0416812A publication Critical patent/BRPI0416812A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"MéTODOS E REAGENTES PARA O TRATAMENTO DE DESORDENS INFLAMATóRIAS". A presente invenção refere-se a um método para tratar um imunoinflamatório administrando um composto de fórmula (I), por exemplo, ibudilast ou KC-764, sozinho ou em combinação com um corticosteróide, pirimidopirimidina tetra-substituída, ou outro composto. A invenção também apresenta composições farmacêuticas incluindo a combinação acima para o tratamento ou prevenção de uma desordem imunoinflamatória.
BRPI0416812-7A 2003-11-21 2004-11-17 métodos e reagentes para o tratamento de desordens inflamatórias BRPI0416812A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52411703P 2003-11-21 2003-11-21
PCT/US2004/038512 WO2005051293A2 (en) 2003-11-21 2004-11-17 Methods and reagents for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
BRPI0416812A true BRPI0416812A (pt) 2007-03-06

Family

ID=34632866

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416812-7A BRPI0416812A (pt) 2003-11-21 2004-11-17 métodos e reagentes para o tratamento de desordens inflamatórias

Country Status (17)

Country Link
US (2) US7709495B2 (pt)
EP (1) EP1689390B1 (pt)
JP (1) JP2007512337A (pt)
KR (1) KR20060120208A (pt)
CN (1) CN1905870A (pt)
AT (1) ATE497763T1 (pt)
AU (1) AU2004292445B2 (pt)
BR (1) BRPI0416812A (pt)
CA (1) CA2546347A1 (pt)
DE (1) DE602004031356D1 (pt)
IL (1) IL175781A0 (pt)
NO (1) NO20062300L (pt)
NZ (1) NZ547389A (pt)
RU (1) RU2006121978A (pt)
SG (1) SG148198A1 (pt)
WO (1) WO2005051293A2 (pt)
ZA (1) ZA200604253B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004031356D1 (de) * 2003-11-21 2011-03-24 Zalicus Inc Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
MX2007006777A (es) 2004-12-06 2007-08-06 Avigen Inc Ibudilast para tratar dolor neuropatico y sindromes asociados.
SI1719507T1 (sl) 2005-04-13 2010-11-30 Astion Dev As Beta adrenoceptor agonisti za zdravljenje bolezni veznega tkiva kože
BRPI0620225A2 (pt) * 2005-12-20 2011-11-01 Tika Läkemedel Ab métodos e sistemas para a distribuição de corticosteróides tendo um perfil farmacocinético aumentado
US20070213308A1 (en) * 2006-01-26 2007-09-13 Lessem Jan N Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
WO2007142924A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
US7585875B2 (en) 2006-06-06 2009-09-08 Avigen, Inc. Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use
US7536799B2 (en) * 2007-06-07 2009-05-26 Keson Industries Chalk line apparatus with strategically located chalk fill opening
US20090005358A1 (en) * 2007-06-26 2009-01-01 Jan Lessem Compositions and methods for treating medical conditions
PT2187882E (pt) 2007-07-11 2013-04-17 Medicinova Inc Tratamento de uma doença neurodegenerativa progressiva com ibudilast
RU2390334C1 (ru) * 2008-12-17 2010-05-27 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию" Способ лечения рассеянного склероза
GB201305714D0 (en) * 2013-03-28 2013-05-15 Ucl Business Plc Method
RU2536274C1 (ru) * 2013-12-20 2014-12-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ лечения бородавок
CN108033959A (zh) * 2018-01-29 2018-05-15 山东省药学科学院 一种异丁司特的化学合成方法
WO2019226515A1 (en) * 2018-05-21 2019-11-28 The University Of North Carolina At Chapel Hill Methods of inhibiting proinflammatory neuroimmune signaling and treating inflammatory disorders
CN113456618A (zh) * 2020-03-31 2021-10-01 天津金耀集团有限公司 一种复方双嘧达莫的吸入制剂及其制备方法
EP4132521A1 (en) * 2020-04-06 2023-02-15 MediciNova, Inc. Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast
CN116887829A (zh) * 2021-01-29 2023-10-13 美迪诺亚公司 治疗化学气体暴露的方法
KR20240019683A (ko) * 2022-08-04 2024-02-14 국민대학교산학협력단 글루쿠론산 또는 이의 유도체를 포함하는 장내 미생물 균총 개선용 조성물
CN115414354A (zh) * 2022-08-29 2022-12-02 西南医科大学 花椒毒素在制备治疗血小板减少症药物中的应用
KR102900597B1 (ko) * 2022-12-09 2025-12-18 대한민국 Impdh 억제제를 포함하는 중증열성혈소판감소증후군 예방 또는 치료용 조성물

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US532248A (en) 1895-01-08 powell
JPS5229318B2 (pt) 1972-03-30 1977-08-01
US4097483A (en) 1974-11-01 1978-06-27 Kyorin Pharmaceutical Co., Ltd. Pyrazolo 1,5-a!pyridines
SE445174B (sv) 1978-03-07 1986-06-09 Sandoz Ag Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans
JPS59167590A (ja) 1983-03-14 1984-09-21 Kyorin Pharmaceut Co Ltd ピラゾロ〔１，５−ａ〕ピリジン誘導体、その製法及びそれを含有する治療剤
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US5254562A (en) 1984-12-03 1993-10-19 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
JP2577049B2 (ja) 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
US4925849A (en) 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
JPH01153634A (ja) * 1987-12-10 1989-06-15 Kyorin Pharmaceut Co Ltd 吸入剤
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US6007840A (en) 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US5208228A (en) 1989-11-13 1993-05-04 Merck & Co., Inc. Aminomacrolides and derivatives having immunosuppressive activity
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5143918A (en) 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
US5626863A (en) 1992-02-28 1997-05-06 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5250678A (en) 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5262533A (en) 1991-05-13 1993-11-16 Merck & Co., Inc. Amino O-aryl macrolides having immunosuppressive activity
US5162334A (en) 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
US5189042A (en) 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5208241A (en) 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
JP2927961B2 (ja) * 1992-02-07 1999-07-28 エム． クリグマン，アルバート 炎症性皮膚病の治療方法
US5284840A (en) 1992-06-12 1994-02-08 Merck & Co., Inc. Alkylidene macrolides having immunosuppressive activity
US6022852A (en) 1993-10-22 2000-02-08 Hexal Ag Pharmaceutical composition containing cyclosporin A
US5693648A (en) 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
US5696130A (en) 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Tricyclic steroid receptor modulator compounds and methods
WO1996041626A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
JPH0920663A (ja) * 1995-07-07 1997-01-21 Teikoku Seiyaku Co Ltd イブジラストを含有する徐放性細粒剤およびその製法
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JPH11222425A (ja) * 1997-10-27 1999-08-17 Ss Pharmaceut Co Ltd 関節疾患治療用関節内投与製剤
ZA9811898B (en) 1997-12-29 2000-06-28 Ortho Mcneil Pharm Inc Anti-Inflammatory Compounds.
US5900249A (en) * 1998-02-09 1999-05-04 Smith; David J. Multicomponent pain relief topical medication
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
US6380207B2 (en) 1998-02-13 2002-04-30 Abbott Laboratories Glucocortiocoid-selective antiinflammatory agents
JP4828003B2 (ja) * 1998-08-10 2011-11-30 杏林製薬株式会社 多発性硬化症治療薬
WO2000034468A2 (en) * 1998-12-11 2000-06-15 Biomira Inc. Muc-1 antagonists and methods of treating immune disorders
JP2000212021A (ja) * 1999-01-14 2000-08-02 Pola Chem Ind Inc 皮膚外用剤
HK1042889B (zh) 1999-04-30 2006-12-29 辉瑞产品公司 糖皮质激素受体调制剂
KR20020024587A (ko) * 1999-05-14 2002-03-30 린다 에스. 스티븐슨 염증 매개성 감염에 대한 항염증 치료
US6593480B2 (en) 1999-09-01 2003-07-15 Abbott Laboratories Glucocorticoid receptor antagonists for treatment of diabetes
IL180679A0 (en) 2000-10-27 2009-02-11 Pfizer Prod Inc Process for the preparation of non-steroidal glucocorticoid receptor modulators
JP2002193911A (ja) 2000-10-28 2002-07-10 Pfizer Prod Inc グルココルチコイドレセプターモジュレーター
JP2003055220A (ja) * 2001-08-09 2003-02-26 Taisho Pharmaceut Co Ltd イブジラスト含有眼科用組成物
JP2003055222A (ja) * 2001-08-16 2003-02-26 Rohto Pharmaceut Co Ltd 安定化された組成物
AU2003214879B2 (en) 2002-01-22 2008-02-07 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
TW200522932A (en) * 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
DE602004031356D1 (de) * 2003-11-21 2011-03-24 Zalicus Inc Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen

Also Published As

Publication number Publication date
EP1689390A2 (en) 2006-08-16
RU2006121978A (ru) 2007-12-27
CA2546347A1 (en) 2005-06-09
NZ547389A (en) 2009-11-27
DE602004031356D1 (de) 2011-03-24
US20100210606A1 (en) 2010-08-19
KR20060120208A (ko) 2006-11-24
WO2005051293A3 (en) 2006-03-02
US7709495B2 (en) 2010-05-04
CN1905870A (zh) 2007-01-31
EP1689390A4 (en) 2008-03-12
NO20062300L (no) 2006-08-21
AU2004292445B2 (en) 2010-02-04
ATE497763T1 (de) 2011-02-15
AU2004292445A1 (en) 2005-06-09
SG148198A1 (en) 2008-12-31
EP1689390B1 (en) 2011-02-09
IL175781A0 (en) 2008-04-13
ZA200604253B (en) 2007-10-31
WO2005051293A2 (en) 2005-06-09
US20050187203A1 (en) 2005-08-25
JP2007512337A (ja) 2007-05-17

Similar Documents

Publication Publication Date Title
NO20062300L (no) Fremgangsmater og reagenser for behandling av inflammatoriske forstyrelser
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
SG147442A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
UA118645C2 (uk) Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
AU2003256755A8 (en) Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
BRPI0413326A (pt) métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel
NO20083240L (no) Sammensetninger og fremgangsmater for forebygging og behandling av kakeksia
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
BRPI0512500A (pt) tratamento ou condições envolvendo desmielinação
BRPI0718469A2 (pt) Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
ATE466595T1 (de) Verbindungen und methoden für das downregulating der effekte von tgf-beta
SG148186A1 (en) Methods and reagents for the treatment of inflammatory disorders
CR9200A (es) Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos
WO2008021048A3 (en) Adp-ribosyltransferase based methods and compositions
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
CY1110368T1 (el) Συνεργιστικος συνδυασμος ο οποιος περιλαμβανει ροφλουμιλαστη και (r,r)-φορμοτερολη
EA200801120A1 (ru) Нафтильные производные в качестве ингибиторов агрегирования бета-амилоида
TW200716561A (en) P38 inhibitors and methods of use thereof
UY29237A1 (es) Metodos detratamiento y prevencion

Legal Events

Date Code Title Description
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 8A E 9A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A, 9A, 10A, 11A, 12A, 13A, 14A E 15A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.